48 patents
Utility
Pyrrolobenzodiazepine-antibody conjugates
14 Nov 23
Patricius Hendrikus Cornelis Van Berkel
Filed: 24 Sep 21
Utility
Pyrrolobenzodiazepine-antibody conjugates
10 Oct 23
Conjugates of an antibody that binds to CD25 with PBD dimers.
Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
Filed: 19 Aug 20
Utility
ANTI-IL-13RALPHA2 Conjugates
14 Sep 23
This disclosure relates to antibody conjugates comprising antibodies that bind specifically to the Interleukin-13 receptor subunit alpha-2 (IL-13Rα2) protein, conjugated to cytotoxic warheads, and associated uses.
Patricius Hendrikus Cornelis VAN BERKEL, Ian KIRBY
Filed: 16 Nov 22
Utility
Site-specific antibody-drug conjugates
18 Jul 23
Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker.
Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
Filed: 14 Nov 19
Utility
Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
4 Jul 23
The disclosure provides conjugates of an isolated humanized anti-CD22 antibody and PBD dimers.
Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
Filed: 26 May 20
Utility
Anti-psma Conjugates
29 Jun 23
This disclosure relates to antibody conjugates comprising antibodies that bind specifically to prostate-specific membrane antigen (PSMA), conjugated to cytotoxic warheads, and associated uses.
Patricius Hendrikus Cornelis VAN BERKEL, Ian KIRBY
Filed: 16 Nov 22
Utility
Combination Therapy
18 May 23
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer.
Jay Marshall FEINGOLD, Patricius Hendrikus Cornelis VAN BERKEL, Jens WUERTHNER, John HARTLEY, Francesca ZAMMARCHI
Filed: 11 Aug 22
Utility
Combination Therapy
27 Apr 23
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer.
Patricius Hendrikus Cornelis VAN BERKEL, Francesca ZAMMARCHI, John HARTLEY
Filed: 8 Jul 19
Utility
Dosage Regime
6 Apr 23
The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs).
Jay Marshall FEINGOLD, David Rodney UNGAR
Filed: 5 Oct 22
Utility
Combination Therapy
30 Mar 23
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer.
Patricius Hendrikus Cornelis VAN BERKEL, Francesca ZAMMARCHI, Jens WUERTHNER
Filed: 6 Nov 20
Utility
Combination therapy with an anti-CD25 antibody-drug conjugate
7 Mar 23
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer.
Patricius Hendrikus Cornelis Van Berkel, Lisa Skelton, Francesca Zammarchi, Jay Marshall Feingold, Jens Wuerthner, John Hartley
Filed: 20 Apr 18
Utility
Pyrrolobenzodiazepine-antibody Conjugates
23 Feb 23
The present invention relates to pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to an antibody.
Patricius Hendrikus Cornelis VAN BERKEL
Filed: 3 Jun 22
Utility
Dosage Regimes
9 Feb 23
The present disclosure relates to novel dosage regimes for the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs).
Jay Marshall FEINGOLD, Jens WUERTHNER
Filed: 15 Jul 22
Utility
Pyrrolobenzodiazepine Resistance
3 Nov 22
The present disclosure relates to methods of determining if a proliferative disorder such as cancer is resistant to treatment with a pyrrolobenzodiazepine (PBD) agent, such as a therapeutic antibody-drug conjugate (ADC) comprising a PBD warhead conjugated to an antibody (PBD-ADC).
John Hartley
Filed: 18 Dec 19
Utility
Pyrrolobenzodiazepine-antibody conjugates
1 Nov 22
The present disclosure relates to pyrrolobenzodiazepines (PBDs) having a labile C2 or N10 protecting group in the form of a linker to an antibody.
Patricius Hendrikus Cornelis Van Berkel
Filed: 20 Jul 21
Utility
Combination Therapy Comprising an ANTI-CD19 Antibody Drug Conjugate and a PI3K Inhibitor or a Secondary Agent
29 Sep 22
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer.
Francesca ZAMMARCHI, Francesco BERTONI
Filed: 8 Jun 20
Utility
Dosage Regimes for the Administration of an ANTI-CD19 Adc
8 Sep 22
The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs).
Jay Marshall Feingold, David Rodney Ungar
Filed: 18 Mar 22
Utility
Dosage regimes for the administration of an anti-CD25 ADC
30 Aug 22
Jay Marshall Feingold, Jens Wuerthner
Filed: 14 Jun 18
Utility
Pyrrolobenzodiazepine-antibody conjugates
12 Jul 22
The present invention relates to pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to an antibody.
Patricius Hendrikus Cornelis Van Berkel
Filed: 8 Feb 18
Utility
Treatment of Car T-cell Toxicity
9 Jun 22
The present disclosure relates to methods for improving the safety profile of adoptive cell transfer therapies.
Tomasz Sablinski
Filed: 8 Feb 19